Home › Agent Hub › Agent Tools › Part D coverage by drug › Namzaric
Agent Tools
Namzaric is a brand of donepezil / memantine. What agents check before quoting it: how many 2027 Part D plans cover it, on which tier, with what restrictions and copays, by plan type, carrier and state.
In 2027, 2,178 of 5,492 Medicare Part D and Medicare Advantage drug plans (39.7%) list Namzaric on their formulary, across 86 of 286 formularies. The most common placement is tier 4 (1,627 plans, 74.7% of those covering it). 25 of the covering plans require prior authorization (1.1%), 55 step therapy and 76 a quantity limit.
62 covering plans charge a flat copay for a 30-day supply at a preferred retail pharmacy after the deductible — median $39.50, 24 of them $0; 2,116 charge coinsurance instead — median 25% of the drug's cost. Once a member's out-of-pocket drug spending reaches $2,400 in 2027, covered drugs cost $0 for the rest of the year.
2026: 2,096 of 5,496 plans covered it (38.1%); 2027: 2,178 of 5,492 (39.7%).
Of 4,367 plans offered in both years, 11 added it to the formulary and 84 dropped it.
Among plans covering it both years, 7 moved it to a higher tier and 164 to a lower one; 0 added prior authorization and 0 removed it.
| Tier | Plans |
|---|---|
| Tier 1 | 28 |
| Tier 2 | 200 |
| Tier 3 | 323 |
| Tier 4 | 1,627 |
| Plan type | Plans covering | Share | Prior auth |
|---|---|---|---|
| Stand-alone Part D (PDP) | 26 of 323 | 8% | 0% |
| Medicare Advantage with drugs (MA-PD) | 1,284 of 3,200 | 40.1% | 1.3% |
| Special needs plans (SNP) | 868 of 1,969 | 44.1% | 0.9% |
| Carrier | Plans covering | Usual tier | Prior auth |
|---|---|---|---|
| Humana | 0 of 846 | No tier listed | 0 |
| UnitedHealthcare | 0 of 830 | No tier listed | 0 |
| Devoted Health | 728 of 728 | Tier 4 | 0 |
| Aetna Medicare | 631 of 631 | Tier 4 | 0 |
| Wellcare | 200 of 268 | Tier 2 | 0 |
| HealthSpring | 0 of 226 | No tier listed | 0 |
| Kaiser Permanente | 0 of 112 | No tier listed | 0 |
| SCAN Health Plan | 0 of 83 | No tier listed | 0 |
| Highmark Blue Cross Blue Shield or Highmark Blue Shield | 0 of 80 | No tier listed | 0 |
| Alignment Health Plan | 0 of 77 | No tier listed | 0 |
| Anthem Blue Cross and Blue Shield | 69 of 74 | Tier 3 | 0 |
| Wellpoint | 50 of 63 | Tier 3 | 0 |
| Priority Health Medicare | 0 of 40 | No tier listed | 0 |
| CarePlus Health Plans, Inc. | 0 of 37 | No tier listed | 0 |
| Zing Health | 36 of 36 | Tier 4 | 0 |
| Capital Blue Cross | 27 of 35 | Tier 4 | 0 |
| Prominence Health Plan | 29 of 29 | Tier 3 | 0 |
| Medica | 0 of 27 | No tier listed | 0 |
| Anthem HealthKeepers | 25 of 26 | Tier 3 | 0 |
| Blue Cross Blue Shield of Michigan | 26 of 26 | Tier 3 | 0 |
| State | Plans covering | Share |
|---|---|---|
| Alabama | 51 of 114 | 44.7% |
| Alaska | 1 of 9 | 11.1% |
| American Samoa | 0 of 1 | 0% |
| Arizona | 58 of 147 | 39.5% |
| Arkansas | 37 of 85 | 43.5% |
| California | 73 of 397 | 18.4% |
| Colorado | 35 of 106 | 33% |
| Connecticut | 35 of 54 | 64.8% |
| Delaware | 14 of 43 | 32.6% |
| District of Columbia | 3 of 12 | 25% |
| Florida | 216 of 545 | 39.6% |
| Georgia | 56 of 149 | 37.6% |
| Guam | 0 of 1 | 0% |
| Hawaii | 24 of 50 | 48% |
| Idaho | 3 of 45 | 6.7% |
| Illinois | 60 of 132 | 45.5% |
| Indiana | 72 of 138 | 52.2% |
| Iowa | 26 of 64 | 40.6% |
| Kansas | 39 of 84 | 46.4% |
| Kentucky | 47 of 121 | 38.8% |
| Louisiana | 47 of 125 | 37.6% |
| Maine | 22 of 52 | 42.3% |
| Maryland | 18 of 49 | 36.7% |
| Massachusetts | 68 of 89 | 76.4% |
| Michigan | 87 of 182 | 47.8% |
| Minnesota | 8 of 63 | 12.7% |
| Mississippi | 46 of 104 | 44.2% |
| Missouri | 81 of 170 | 47.6% |
| Montana | 0 of 27 | 0% |
| Nebraska | 20 of 51 | 39.2% |
| Nevada | 29 of 100 | 29% |
| New Hampshire | 6 of 25 | 24% |
| New Jersey | 29 of 73 | 39.7% |
| New Mexico | 13 of 68 | 19.1% |
| New York | 119 of 215 | 55.3% |
| North Carolina | 63 of 176 | 35.8% |
| North Dakota | 3 of 26 | 11.5% |
| Northern Mariana Islands | 0 of 1 | 0% |
| Ohio | 81 of 171 | 47.4% |
| Oklahoma | 19 of 81 | 23.5% |
| Oregon | 36 of 92 | 39.1% |
| Pennsylvania | 115 of 323 | 35.6% |
| Puerto Rico | 0 of 64 | 0% |
| Rhode Island | 7 of 29 | 24.1% |
| South Carolina | 30 of 89 | 33.7% |
| South Dakota | 7 of 30 | 23.3% |
| Tennessee | 87 of 156 | 55.8% |
| Texas | 180 of 407 | 44.2% |
| U.S. Virgin Islands | 0 of 1 | 0% |
| Utah | 14 of 53 | 26.4% |
| Vermont | 2 of 14 | 14.3% |
| Virginia | 46 of 144 | 31.9% |
| Washington | 38 of 114 | 33.3% |
| West Virginia | 16 of 69 | 23.2% |
| Wisconsin | 20 of 96 | 20.8% |
| Wyoming | 2 of 13 | 15.4% |
Medicare Part D paid for 175,650 30-day fills of Namzaric in 2024 for about 18,215 enrollees, at an average total cost of $510.04 per 30-day fill (CMS Part D Prescribers by Geography and Drug, national).
Price Namzaric and the rest of a client's list on every plan in their county.
Estimate Namzaric costs by plan
Free tools for licensed insurance agents. Data from CMS public files; verify with plan documents before advising a client.
Counts are over every Medicare Advantage drug plan and stand-alone Part D plan in the CMS monthly formulary files, excluding employer plans. A plan counts as covering a drug when any strength or form of it is on the plan’s formulary; the tier, prior authorization, step therapy and quantity limit shown are the most favorable version on that formulary. Copays are for a 30-day supply at a preferred retail pharmacy after the deductible. This is a reference for licensed agents, not a plan recommendation; verify with the plan’s formulary before advising a client. Source: CMS Part D formulary files (release 10/08/2026). CMS formulary data.